期刊文献+

系统性红斑狼疮靶向治疗进展 被引量:11

Advances in Targeted Therapy of Systemic Lupus Erythematosus
原文传递
导出
摘要 系统性红斑狼疮(SLE)是一种病因及发病机制至今尚不明确的自身免疫性疾病。其发病人数逐年增加,而传统治疗方法疗效有限。近年来系统性红斑狼疮靶向治疗的研究提供了更多的方法及策略,如B细胞靶向治疗、细胞因子靶向治疗、阻断联合刺激信号、T细胞靶向治疗等。其中以B细胞靶向治疗最为成熟,贝利木单抗为最好的例子,针对B细胞刺激细胞因子(BLyS)进行阻断,目前已通过美国食品和药物管理向批准用于SLE的治疗。本文参考国内外文献综述分析了新的治疗方法——靶向治疗的进展,特别着重于药物的临床试验。 The causes and mechanisms of systemic lupus erythematosus(SLE) are still not clear. The morbidity increases rapidly, but traditional treatment efficacy is not satisfactory. Recent insights into targeted therapy provide new selective therapies of SLE, such as B cell targeted strategies, cytokine directed therapy, costimulation blockage, and T cell targeted strategies. The best exam- ple is Belimumab, which targets the B cell cytokine BLyS and has now received Food and Drug Administration (FDA) approval for its use in SLE. This paper reviewed the targeted therapy for SLE, with particular focus on new drug clinical trials.
出处 《武汉大学学报(医学版)》 CAS 北大核心 2014年第1期160-164,共5页 Medical Journal of Wuhan University
关键词 系统性红斑狼疮 治疗 进展 Systemic Lupus Erythematosus Treatment Progress
  • 相关文献

参考文献23

  • 1Ferndndez-Nebro A, Marsal S, Chatham W,et al. Sys- temic Lupus Erythematosus: Genomics, Mechanisms, and Therapies. Cli Dev Immunol, 2012,16 : 4-5.
  • 2李坤鹏,张江林.B细胞靶向治疗在系统性红斑狼疮的应用[J].军医进修学院学报,2009,30(1):35-36. 被引量:1
  • 3Ramos-casals M, Sanz I, Bosch X, et al. B-cell-depleting therapy in systemic lupus erythematosus[J]. American J Med,2012,125(4) :327-336.
  • 4Arbuckle MR, McClain MT, Rubertone MV,et al. De- velopment of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003, 349(16):1 526-1 533.
  • 5Lo MS, Tsokos GC. Treatment of systemic lupus ery- thematosus:new advances in targeted therapy[J]. Ann N Y Acad Sci,2012,1 247:138-152.
  • 6Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus ery- thematosus. Arthritis Rheum, 2002,46 (10) : 2 673- 2 677.
  • 7Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized,double- blind,phase II/III systemic lupus erythematosus evalu- ation of rituximab trial[J]. Arthritis Rheum, 2010,62 (1) :222-233.
  • 8Furie R,Looney J,Rovin B,et al. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase iii lu- nar study[J]. Ann Rheum Dis, 2010,69 : 549.
  • 9Ramos-Casals M,Diaz-Lagares C,Khamashta MA. Rit- uximab and lupus: good in real life, bad in controlled trials-comment on the article by Lu et al[J]. Arthritis Rheum, 2009,61(9):1 281-1 282.
  • 10Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Ritux- imab in systemic lupus erythematosus:a systematic re- view of off-label use in 188 cases[J]. Lupus, 2009,18 (9) :767-776.

二级参考文献35

  • 1穆荣,戴振鹏,栗占国,高晓明.T细胞疫苗治疗系统性红斑狼疮的初步临床研究[J].中华内科杂志,2004,43(8):568-571. 被引量:7
  • 2杨佳荟,沈茜,赵东宝,蔡青,韩星海.可诱导共刺激分子在系统性红斑狼疮病人外周血T细胞亚群的表达及与临床的关系[J].中华医学杂志,2005,85(5):318-323. 被引量:4
  • 3Hoffman RW. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol, 2004, 113: 4-13.
  • 4Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford), 2003, 42: 214-222.
  • 5Alvarado-Sanchez B, Hemandez-Castro B, Portales-Perez D, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun, 2006, 27: 110-118.
  • 6Park Y, Lee SK, Kim DS, et al. Elevated IL-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol, 1998, 16: 283-288.
  • 7Llorente L, Richand-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin 10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum, 2000, 43: 1790-1800.
  • 8Tackey E, Lipsky PE, Illei G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus, 2004, 13: 339- 343.
  • 9Belmont HM, Buyon J, Giorno R, et al. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: The Shwartzman phenomenon revisited. Arthritis Rheum, 1994, 37: 376-383.
  • 10Kalled SL, Cutler AH, Datta SK, et al. Anti-CD40 ligand antibody treatment of SNF 1 mice with established nephritis: preservation of kidney function. J Immunol, 1998, 160: 2158-2165.

同被引文献91

引证文献11

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部